+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

In Vivo Contract Research Organization (CRO) - Global Strategic Business Report

  • PDF Icon

    Report

  • 89 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303436
The global market for In Vivo Contract Research Organization (CRO) was estimated at US$4.5 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global In Vivo Contract Research Organization (CRO) Market - Key Trends and Drivers Summarized

Why Is In Vivo Contract Research Organization (CRO) Crucial for Preclinical and Clinical Research?

In vivo Contract Research Organizations (CROs) are essential for conducting preclinical and clinical research in drug development, focusing on studies conducted within living organisms. These CROs provide services such as animal testing, pharmacokinetics, toxicology, and efficacy studies that are vital to the early stages of drug development. In vivo studies help assess how a drug behaves in a biological system, providing critical data on its safety, bioavailability, and potential therapeutic effects. Outsourcing these services to specialized CROs allows pharmaceutical and biotechnology companies to reduce costs, accelerate research timelines, and access expertise in regulatory compliance and animal testing protocols, making in vivo CROs indispensable in the development pipeline.

How Are Technological Advancements Shaping the In Vivo CRO Market?

Technological advancements in imaging, genomics, and data analytics are significantly enhancing the capabilities of in vivo CROs. Non-invasive imaging techniques, such as MRI, PET, and CT scans, have improved the ability to monitor drug effects and disease progression in real-time, providing more precise and detailed insights into drug efficacy and toxicity. Furthermore, advancements in genetic engineering and CRISPR technology have expanded the use of animal models, allowing for more targeted studies on specific diseases or genetic conditions. Data analytics and AI are also revolutionizing the in vivo CRO landscape by enabling faster and more accurate analysis of preclinical data, reducing the time it takes to make critical decisions in the drug development process.

How Do Market Segments Define the Growth of the In Vivo CRO Market?

Service types include toxicology, pharmacokinetics, pharmacodynamics, and efficacy studies, with toxicology services accounting for the largest market share due to regulatory requirements for drug safety testing. Therapeutic areas served by in vivo CROs include oncology, cardiovascular diseases, infectious diseases, and neurological disorders, with oncology leading the market as cancer remains a primary focus of drug development. End-users include pharmaceutical companies, biotechnology firms, and academic institutions, with pharmaceutical companies being the dominant segment due to their high demand for outsourced preclinical services. The market is also expanding in emerging regions, where CRO services are increasingly outsourced to countries with lower operational costs.

What Factors Are Driving the Growth in the In Vivo CRO Market?

The growth in the in vivo CRO market is driven by several factors, including increasing demand for preclinical and clinical research, the rising complexity of drug development, and the growing trend of outsourcing research activities. As pharmaceutical companies face mounting pressure to bring new drugs to market faster and more cost-effectively, they are turning to specialized CROs to handle in vivo studies, reducing the burden on internal resources. The growing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving demand for in vivo studies to develop new therapeutics. Additionally, advancements in personalized medicine and biologics are increasing the complexity of preclinical research, making CROs a critical component of the drug development process.

Scope of the Study

The report analyzes the In Vivo Contract Research Organization (CRO) market, presented in terms of market value (US$ Million). The analysis covers the key segments and geographic regions outlined below.

Segments

Modality (Smalll Molecules Modality, Large Molecules Modality); Model Type (Rodent-based Model, Non-Rodent based Model); Application (Oncology Application, CNS Application, Diabetes Application, Obesity Application, Pain Management Application, Other Applications)

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Smalll Molecules Modality segment, which is expected to reach US$4.9 Billion by 2030 with a CAGR of a 5.9%. The Large Molecules Modality segment is also set to grow at 9.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.3 Billion in 2023, and China, forecasted to grow at an impressive 6.8% CAGR to reach $1.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global In Vivo Contract Research Organization (CRO) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global In Vivo Contract Research Organization (CRO) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global In Vivo Contract Research Organization (CRO) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Global In Vivo Contract Research Organization (CRO) Market such as American Preclinical Services, LLC., Charles River Laboratories, Covance Inc., Evotec (US), Inc., ICON Plc and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Global In Vivo Contract Research Organization (CRO) Market report include:

  • American Preclinical Services, LLC.
  • Charles River Laboratories
  • Covance Inc.
  • Evotec (US), Inc.
  • ICON Plc
  • inVentiv Health
  • Parexel International
  • Pharmaceutical Product Development, LLC (PPD)
  • Quintiles
  • Theorem Clinical research
  • WuXi AppTec, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • In Vivo Contract Research Organization (CRO) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Outsourcing of R&D Activities Spurs Growth of In Vivo CRO Services
  • Growing Focus on Drug Discovery and Development Expands Market Opportunity
  • Rising Costs of In-House Research Drives Outsourcing to In Vivo CROs
  • Technological Advancements in Imaging and Animal Models Strengthen Business Case for CRO Services
  • Growth of Biotechnology and Pharmaceutical Sectors Fuels Demand for Preclinical Services
  • Accelerating Drug Approval Timelines Drives Need for CRO Efficiency
  • Increased Adoption of Personalized Medicine Propels Use of Specialized CROs
  • Focus on Reducing Time-to-Market for New Drugs Sustains Demand for CRO Services
  • Rising Number of Clinical Trials Generates Demand for In Vivo Testing
  • Expansion of Biologics and Biosimilars Market Expands Opportunities for CROs
  • Need for Compliance with International Standards Spurs Use of Reputable CROs
  • Growth of Toxicology and Safety Testing Services Strengthens CRO Market
  • Increasing Focus on Non-Animal Testing Methods Propels Innovation in CROs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World In Vivo Contract Research Organization (CRO) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Smalll Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Smalll Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Smalll Molecules Modality by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Large Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Large Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Large Molecules Modality by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Rodent-based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Rodent-based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Rodent-based Model by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Non-Rodent based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Non-Rodent based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Non-Rodent based Model by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for CNS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for CNS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for CNS Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Pain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Pain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for Pain Management Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
REST OF EUROPE
ASIA-PACIFIC
  • In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned

  • American Preclinical Services, LLC.
  • Charles River Laboratories
  • Covance Inc.
  • Evotec (US), Inc.
  • ICON Plc
  • inVentiv Health
  • Parexel International
  • Pharmaceutical Product Development, LLC (PPD)
  • Quintiles
  • Theorem Clinical research
  • WuXi AppTec, Inc.

Table Information